A life-threatening central nervous system-tuberculosis inflammatory reaction nonresponsive to corticosteroids and successfully controlled by infliximab in a young patient with a variant of juvenile idiopathic arthritis

Journal of Clinical Rheumatology

Volumn 18, Issue 4, 2012, Pages 189-191

  Jorge, Jaimes Hernández ^a   Graciela, Cárdenas ^b   Pablo, Aranda Pereira ^a   Luis, Soto Hernández José ^b  

^a Secretaria de Finanzas del Distrito Federal   (Mexico)

^b SECRETARÍA DE SALUD   (Mexico)

Author keywords

central nervous tuberculosis infection; infliximab; juvenile idiopathic arthritis

Indexed keywords

ADENOSINE DEAMINASE; CHLOROQUINE; CIPROFLOXACIN; DEFLAZACORT; DEXAMETHASONE; ETHAMBUTOL; GADOLINIUM; GLUCOSE; IBUPROFEN; INFLIXIMAB; ISONIAZID; LOMEFLOXACIN; METHOTREXATE; MOXIFLOXACIN; PREDNISONE; PROTEIN; PYRAZINAMIDE; RIFAMPICIN; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA;

ACHILLES TENDON; ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; BRAIN INFARCTION; CASE REPORT; CELLULAR IMMUNITY; CEREBROSPINAL FLUID ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONVALESCENCE; DISEASE COURSE; DISEASE EXACERBATION; DOPPLER ECHOGRAPHY; DRUG DOSE INCREASE; DRUG MEGADOSE; ENTHESITIS; FEVER; FOLLOW UP; FOOT PAIN; GLUCOSE BRAIN LEVEL; HEADACHE; HEEL PAIN; HOSPITAL READMISSION; HUMAN; HYDROCEPHALUS; INTRACRANIAL TUBERCULOMA; JUVENILE RHEUMATOID ARTHRITIS; LOW DRUG DOSE; MALE; MEDICAL HISTORY; METATARSOPHALANGEAL JOINT; MILIARY TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PLEOCYTOSIS; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; REMISSION; SACROILIITIS; SINGLE DRUG DOSE; THORAX RADIOGRAPHY; TREATMENT DURATION; TUBERCULOUS MENINGITIS; UNSTEADINESS; URINE CULTURE; VASCULITIS; VOMITING;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ANTITUBERCULAR AGENTS; ARTHRITIS, JUVENILE RHEUMATOID; GLUCOCORTICOIDS; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MYCOBACTERIUM TUBERCULOSIS; TOMOGRAPHY, X-RAY COMPUTED; TUBERCULOSIS, MENINGEAL; TUBERCULOSIS, MILIARY; YOUNG ADULT;

EID: 84862193102     PISSN: 10761608     EISSN: 15367355     Source Type: Journal    
DOI: 10.1097/RHU.0b013e318258b725     Document Type: Article

References (17)

1. Greenberg S. Infections in the immunocompromised rheumatologic patient. Crit Care Clin. 2002;18:931-956.
2. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with Infliximab, a tumor necrosis alpha-neutralizing agent. N Engl J Med. 2001;345:1098-1104.
3. García Vidal C, Rodriguez Fernández S, Martínez Lacasa J, et al. Paradoxical response to anti-tuberculous therapy in infliximab-treated patients with disseminated tuberculosis. Clin Infect Dis. 2005;40:756-759.
4. Gardam MA, Keystone EC, Menzies R, et al. AntiYtumor necrosis factor agent and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3:148-155.
5. Strady C, Brochot P, Ainine K, et al. Tuberculosis during treatment by TNF alpha-inhibitors. Presse Med. 2006;35(11 Pt 2):1765-1772.
6. Hassan TM, Keane J, McLaughlin AM. Paradoxical reaction causing tuberculous arthritis and soft-tissue abscess in a nonYHIV infected, lymphopenic, vitamin D deficient patient with disseminated tuberculosis. A coincidence or an immunological conundrum? Joint Bone Spine. 2011;78:322-323.
7. Wallis RS. Tumor necrosis factor antagonist: structure, function, and tuberculosis risks. Lancet Infect Dis. 2008;8:601-611.
8. Murdoch DM, Venter WDF, Van Rie A, et al. Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther. 2007;4:1-10.
9. Eshun-Wilson I, Havers F, Nachega JB, et al. Evaluation of paradoxical TB-associated IRIS with the use of standardized case definitions for resource-limited settings. J Int Assoc Physicians AIDS Care (Chic). 2010;9:104-108
10. Blackmore TK, Manning L, Taylor WJ, et al. Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes. Clin Infect Dis. 2008;47:e83Ye85.
11. van er Harst JJ, Luijckx GJ. Treatment of central nervous system tuberculosis infections and neurological complications of tuberculosis treatment. Curr Pharm Des. 2011;17:2940-2947.
12. Schoeman JF, Andronikou S, Stefan DC, et al. Tuberculous meningitisYrelated optic neuritis: recovery of vision with thalidomide in 4 consecutive cases. J Child Neurol. 2010;25:822-828
13. Roberts MT, Mendelson M, Meyer P, et al. The use of thalidomide in the treatment of intracranial tuberculomas in adults: two case reports. J Infect. 2003;47:251-255.
14. Buonsenso D, Serranti D, Valentini P. Management of central nervous system tuberculosis in children: light and shade. Eur Rev Med Pharmacol Sci. 2010;47:845-853.
15. Török ME, Nguyen DB, Tran TH, et al. Dexamethasone and long-term outcome of tuberculous meningitis in Vietnamese adults and adolescents. PLoS One. 2011;6:e27821.
16. Rivoisy C, Amrouche L, Carcelain G, et al. Paradoxical exacerbation of tuberculosis after TNF> antagonist discontinuation: beware of immune reconstitution inflammatory syndrome. Joint Bone Spine. 2011;78:312-315.
17. Wallis RS, van Vuuren C, Potgieter S. Adalimumab treatment of life-threatening tuberculosis. Clin Infect Dis. 2009;48:1429-1432.